{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:12:41Z","timestamp":1768522361542,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ygyno.2009.09.018","type":"journal-article","created":{"date-parts":[[2009,10,19]],"date-time":"2009-10-19T04:03:24Z","timestamp":1255925004000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma"],"prefix":"10.1016","volume":"116","author":[{"given":"Koji","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele L.","family":"Eno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight D.","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil B.","family":"Rosenshein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.09.018_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2004.04.077","article-title":"Chemotherapy sensitivity and resistance assays: a systematic review","volume":"22","author":"Samson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.018_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jnci\/82.7.582","article-title":"Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures","volume":"82","author":"Kern","year":"1990","journal-title":"J. Natl. Cancer. Inst."},{"key":"10.1016\/j.ygyno.2009.09.018_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/gyno.2002.6797","article-title":"Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients","volume":"87","author":"Holloway","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.018_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.24654","article-title":"Low drug resistance to both platinum and taxane chemotherapy on an in-vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian, and peritoneal cancer","author":"Matsuo","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.09.018_bib5","unstructured":"Oncotech, EDR Assay\u00ae, http:\/\/www.exiqon.com\/dxps\/Documents\/edr_4_pager.pdf (as of May 6, 2009)."},{"key":"10.1016\/j.ygyno.2009.09.018_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.09.018_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2008.05.019","article-title":"Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays","volume":"110","author":"McAlpine","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.018_bib8","article-title":"Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas","author":"Matsuo","year":"2009","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2009.09.018_bib9","first-page":"41","article-title":"Heterogeneity of drug resistance in human breast and ovarian cancers","volume":"4","author":"Kern","year":"1998","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.ygyno.2009.09.018_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2005.04.036","article-title":"Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma","volume":"98","author":"Tewari","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.018_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1067\/S0002-9378(03)00629-X","article-title":"Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy","volume":"189","author":"Loizzi","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2009.09.018_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1006\/gyno.1998.5109","article-title":"Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer","volume":"70","author":"Eltabbakh","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.018_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/gyno.1995.1145","article-title":"The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial","volume":"57","author":"M\u00e4enp\u00e4\u00e4","year":"1995","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809007173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809007173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:24:19Z","timestamp":1758770659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809007173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0090825809007173"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.09.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}